ClinicalTrials.gg
CompletedNCT02870400Updated Feb 20, 2017

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

A Phase 1 interventional study of REGN2477 and Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-20.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The primary objective of the study is to assess the safety and tolerability of single ascending doses of REGN2477 in healthy women not of childbearing potential.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy women not of between 18 and 65 years of age, with no significant health issues or abnormal laboratory findings
  2. A (BMI) between 18 to 30 kg/m2, inclusive
  3. Provide a signed

Exclusion criteria

Exclusion Criteria:

  1. Significant illness or history of significant illness
  2. abnormal CBC, clinical chemistry, and urine analysis at screening
  3. Current smoker or former smoker who has stopped smoking within 3 months prior to screening
  4. Positive urine drug test results during screening, or history of drug or alcohol abuse
  5. Donation or loss of, blood within 8 weeks prior to screening, or plasma up to 14 days prior to screening
  6. History of diabetes
  7. Abnormal blood pressure (BP)
  8. History of gynecological disorders or ; history of breast malignancies; or history of benign gynecological or breast lesions that require medical treatment or follow up
  9. Reduced renal function
  10. Known history of chronic hepatitis or
  11. Clinically significant abnormalities
  12. Participation in any clinical research study within 30 days, or 5 halflives, of the study drug, whichever is greater, or for longer periods per regional requirements, prior to the screening visit
  13. Exposure to any biological drugs within 3 months of the screening visit (the name of the drug and duration of previous exposure will be recorded). Vaccination within 4 weeks of screening visit.
  14. History of reactions to vaccines or other biologics
  15. History of hypersensitivity to doxycycline or other tetracycline antibiotics
  16. History of osteoporosis requiring osteoporosis treatments such as PTH, bisphosphonates, and denosumab
  17. Subject using hormone replacement therapy or thyroid replacement therapy will be excluded, unless they have been on stable doses of such therapy for at least 6 months and will remain on the same stable dose through the duration of the trial
  18. Use of systemic , including oral glucocorticoids, for more than 10 days, within 3 months prior to screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    REGN2477

    Cohorts 1 - 5 will receive REGN2477

    Drug: REGN2477

  • Experimental
    Placebo

    Cohorts 1 - 5 will receive placebo

    Drug: Placebo

Interventions

  • Participants will receive ascending doses of REGN2477

  • DrugPlacebo

    Participants will receive matching placebo

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events (TEAEs) through day 113 in participants treated with REGN2477

    Time frame: Day 1 to Day 113

Secondary outcomes

  1. Pharmacokinetic profile of REGN2477, assessed via serum concentrations of REGN2477 over time

    Time frame: Day 1 to Day 113

  2. Immunogenicity of REGN2477, as determined by the presence or absence of Anti-drug antibody (ADA) to REGN2477 over time

    Time frame: Day 1 to Day 113

07

Study locations

1 site
  • Antwerp, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2016
First posted
Aug 17, 2016
Start
Jul 2016
Primary completionActual
Jan 12, 2017
CompletionActual
Jan 12, 2017
Last update
Feb 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02870400
Responsible party
Sponsor
First posted
Aug 17, 2016
Start date
Jul 2016
Primary completion
Jan 12, 2017
Completion
Jan 12, 2017
Last update
Feb 20, 2017

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garetosmab

Start the discussion